Claudia Valverde
Overview
Explore the profile of Claudia Valverde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
575
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Frezza A, Leonard H, Aggerholm-Pedersen N, Badalamenti G, Baili P, Baldi G, et al.
PLoS One
. 2024 Aug;
19(8):e0308387.
PMID: 39133752
Introduction: Epithelioid hemangioendothelioma (EHE) is an ultra-rare sarcoma, marked by distinctive molecular and pathological features and with a variable clinical behavior. Its natural history is still partially understood, reliable prognostic...
12.
Green D, Ewijk R, Tirtei E, Andreou D, Baecklund F, Baumhoer D, et al.
Clin Cancer Res
. 2024 Jun;
30(16):3395-3406.
PMID: 38869831
Osteosarcoma and Ewing sarcoma are bone tumors mostly diagnosed in children, adolescents, and young adults. Despite multimodal therapy, morbidity is high and survival rates remain low, especially in the metastatic...
13.
Moura D, Mondaza-Hernandez J, Sanchez-Bustos P, Pena-Chilet M, Cordero-Varela J, Lopez-Alvarez M, et al.
Cell Mol Life Sci
. 2024 May;
81(1):219.
PMID: 38758230
HMGA1 is a structural epigenetic chromatin factor that has been associated with tumor progression and drug resistance. Here, we reported the prognostic/predictive value of HMGA1 for trabectedin in advanced soft-tissue...
14.
Kokkali S, Georgaki E, Mandrakis G, Valverde C, Theocharis S
Cells
. 2023 Nov;
12(22).
PMID: 37998367
Genomic profiling has improved our understanding of the pathogenesis of different cancers and led to the development of several targeted therapies, especially in epithelial tumors. In this review, we focus...
15.
Hernando-Calvo A, Vila-Casadesus M, Bareche Y, Gonzalez-Medina A, Abbas-Aghababazadeh F, Lo Giacco D, et al.
Med
. 2023 Aug;
4(10):710-727.e5.
PMID: 37572657
Background: Immunotherapy is effective, but current biomarkers for patient selection have proven modest sensitivity. Here, we developed VIGex, an optimized gene signature based on the expression level of 12 genes...
16.
Martin-Broto J, Valverde C, Hindi N, Vincenzi B, Martinez-Trufero J, Grignani G, et al.
Mol Cancer
. 2023 Aug;
22(1):127.
PMID: 37559050
Background: Approximately 15% of adult GIST patients harbor tumors that are wild-type for KIT and PDGFRα genes (KP-wtGIST). These tumors usually have SDH deficiencies, exhibit a more indolent behavior and...
17.
Perez-Fidalgo J, Ortega E, Ponce J, Redondo A, Sevilla I, Valverde C, et al.
Ther Adv Med Oncol
. 2023 Apr;
15:17588359231157645.
PMID: 37007636
Uterine sarcomas are very infrequent and heterogeneous entities. Due to its rarity, pathological diagnosis, surgical management, and systemic treatment are challenging. Treatment decision process in these tumors should be taken...
18.
Martin-Broto J, Redondo A, Moura D, Valverde C, Morales J, Lopez-Pousa A, et al.
Nat Commun
. 2022 Oct;
13(1):6278.
PMID: 36271011
Desmoid fibromatosis (DF) are mesenchymal neoplasms, with potential aggressive course and relevant clinical impact. New systemic therapy modalities are needed in this symptomatic/progressive population. In this multicenter, phase II trial...
19.
Pantaleo M, Heinrich M, Italiano A, Valverde C, Schoffski P, Grignani G, et al.
BMC Cancer
. 2022 May;
22(1):511.
PMID: 35524239
Background: Acquired resistance to approved tyrosine kinase inhibitors limits their clinical use in patients with gastrointestinal stromal tumor (GIST). This study investigated the safety, tolerability and efficacy of alpelisib, a...
20.
Vasquez-Dongo C, Rivas A, Ferrer B, Bodet D, Valverde C, Delbene C, et al.
Rev Esp Patol
. 2022 Apr;
55(2):139-144.
PMID: 35483770
Lipoblastoma-like tumor of the vulva (LBLTV) was first described as a benign mesenchymal neoplasia; it was not recognized as a separate diagnosis in the 2013 WHO classification of soft-tissue tumors....